疫苗衍生脊髓灰质炎病毒暴发的最新情况——全球,2019年7月至2020年2月
本文更新了2019年7月至2020年2月全球循环疫苗衍生脊髓灰质炎病毒(cVDPV)暴发情况:共报告33起cVDPV暴发,其中31起(94%)为cVDPV2,18起(58%)为新发。全球消灭脊髓灰质炎行动倡议计划于2020年中期引入新型口服脊髓灰质炎疫苗2型(nOPV2),并预计2021年用于cVDPV2暴发应对。
要点
- 2019年7月至2020年2月全球报告33起cVDPV暴发,其中31起(94%)为cVDPV2。
- 31起cVDPV2暴发中18起(58%)为新发,与单价2型OPV使用及免疫覆盖率不足有关。
- 全球消灭脊髓灰质炎行动倡议计划2020年中期引入nOPV2,2021年用于cVDPV2暴发应对。
核心结论
- 2019年7月至2020年2月全球共报告33起cVDPV暴发,其中31起(94%)为cVDPV2,18起(58%)为新发。
- 全球消灭脊髓灰质炎行动倡议计划2020年中期引入nOPV2,若其成功限制新发VDPV2,则预计2021年用nOPV2替代Sabin单价2型OPV用于cVDPV2暴发应对。
研究设计与样本
- 本文为全球cVDPV暴发监测更新报告,数据截至2020年3月25日。
主要发现
- 2019年7月至2020年2月报告33起cVDPV暴发,其中31起(94%)为cVDPV2。
- 31起cVDPV2暴发中18起(58%)为新发。
- 新的cVDPV2暴发可由单价2型OPV使用播散,原因包括应对区内单价2型OPV覆盖率不理想及近期接种单价2型OPV的儿童或接触者流出应对区。
- 新的cVDPV2暴发也可因意外暴露于含Sabin OPV2的疫苗(如残留的应对用单价2型OPV或三价OPV)而发生。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Circulating vaccine-derived polioviruses (cVDPVs) can emerge in areas with low poliovirus immunity and cause outbreaks* of paralytic polio (1-5). Among the three types of wild poliovirus, type 2 was declared eradicated in 2015 (1,2). The use of trivalent oral poliovirus vaccine (tOPV; types 1, 2, and 3 Sabin strains) ceased in April 2016 via a 1-month-long, global synchronized switch to bivalent OPV (bOPV; types 1 and 3 Sabin strains) in immunization activities (1-4). Monovalent type 2 OPV (mOPV2; type 2 Sabin strain) is available for cVDPV type 2 (cVDPV2) outbreak response immunization (1-5). The number and geographic breadth of post-switch cVDPV2 outbreaks have exceeded forecasts that trended toward zero outbreaks 4 years after the switch and assumed rapid and effective control of any that occurred (4). New cVDPV2 outbreaks have been seeded by mOPV2 use, by both suboptimal mOPV2 coverage within response zones and recently mOPV2-vaccinated children or contacts traveling outside of response zones, where children born after the global switch are fully susceptible to poliovirus type 2 transmission (2-4). In addition, new emergences can develop by inadvertent exposure to Sabin OPV2-containing vaccine (i.e., residual response mOPV2 or tOPV) (4). This report updates the January 2018-June 2019 report with information on global cVDPV outbreaks during July 2019-February 2020 (as of March 25, 2020)† (2). Among 33 cVDPV outbreaks reported during July 2019-February 2020, 31 (94%) were cVDPV2; 18 (58%) of these followed new emergences. In mid-2020, the Global Polio Eradication Initiative (GPEI) plans to introduce a genetically stabilized, novel OPV type 2 (nOPV2) that has a lower risk for generating VDPV2 than does Sabin mOPV2; if nOPV2 is successful in limiting new VDPV2 emergences, GPEI foresees the replacement of Sabin mOPV2 with nOPV2 for cVDPV2 outbreak responses during 2021 (2,4,6).
引用
- Alleman MM, Jorba J, Greene SA, et al. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, July 2019-February 2020. MMWR Morb Mortal Wkly Rep. 2020. PMID: 32324719. doi:10.15585/mmwr.mm6916a1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。